Current Landscape of Antiviral Drug Discovery

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2016 Mar 11

PMID 26962437

Citations 19

Authors

Wade Blair

Christopher Cox

Affiliations

Soon will be listed here.

Abstract

Continued discovery and development of new antiviral medications are paramount for global human health, particularly as new pathogens emerge and old ones evolve to evade current therapeutic agents. Great success has been achieved in developing effective therapies to suppress human immunodeficiency virus (HIV) and hepatitis B virus (HBV); however, the therapies are not curative and therefore current efforts in HIV and HBV drug discovery are directed toward longer-acting therapies and/or developing new mechanisms of action that could potentially lead to cure, or eradication, of the virus. Recently, exciting early clinical data have been reported for novel antivirals targeting respiratory syncytial virus (RSV) and influenza (flu). Preclinical data suggest that these new approaches may be effective in treating high-risk patients afflicted with serious RSV or flu infections. In this review, we highlight new directions in antiviral approaches for HIV, HBV, and acute respiratory virus infections.

Citing Articles

A multiplex method for rapidly identifying viral protease inhibitors.

Hong S, Resnick S, Iketani S, Cha J, Albert B, Fazekas C Mol Syst Biol. 2025; 21(2):158-172.

PMID: 39762652 PMC: 11790949. DOI: 10.1038/s44320-024-00082-1.

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.

Oey A, McClure M, Symons J, Chanda S, Fry J, Smith P PLoS One. 2023; 18(7):e0288271.

PMID: 37467213 PMC: 10355467. DOI: 10.1371/journal.pone.0288271.

Respiratory Syncytial Virus Infection: Treatments and Clinical Management.

Malik S, Ahmad T, Muhammad K, Waheed Y Vaccines (Basel). 2023; 11(2).

PMID: 36851368 PMC: 9962240. DOI: 10.3390/vaccines11020491.

Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals.

Sadat Mousavi Maleki M, Sardari S, Ghandehari Alavijeh A, Madanchi H Int J Pept Res Ther. 2022; 29(1):5.

PMID: 36466430 PMC: 9702942. DOI: 10.1007/s10989-022-10477-z.

G-Quadruplex Targeting in the Fight against Viruses: An Update.

Ruggiero E, Zanin I, Terreri M, Richter S Int J Mol Sci. 2021; 22(20).

PMID: 34681641 PMC: 8538215. DOI: 10.3390/ijms222010984.

References

Margolis D, Boffito M . Long-acting antiviral agents for HIV treatment. Curr Opin HIV AIDS. 2015; 10(4):246-52. PMC: 5638428. DOI: 10.1097/COH.0000000000000169. View

De Palma A, Vliegen I, De Clercq E, Neyts J . Selective inhibitors of picornavirus replication. Med Res Rev. 2008; 28(6):823-84. DOI: 10.1002/med.20125. View

Corti D, Voss J, Gamblin S, Codoni G, Macagno A, Jarrossay D . A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333(6044):850-6. DOI: 10.1126/science.1205669. View

Plant H, Stacey C, Tiong-Yip C, Walsh J, Yu Q, Rich K . High-Throughput Hit Screening Cascade to Identify Respiratory Syncytial Virus (RSV) Inhibitors. J Biomol Screen. 2015; 20(5):597-605. DOI: 10.1177/1087057115569428. View

Malykhina O, Yednak M, Collins P, Olivo P, Peeples M . A respiratory syncytial virus replicon that is noncytotoxic and capable of long-term foreign gene expression. J Virol. 2011; 85(10):4792-801. PMC: 3126208. DOI: 10.1128/JVI.02399-10. View

Ermis F, Tasci E . New treatment strategies for hepatitis C infection. World J Hepatol. 2015; 7(17):2100-9. PMC: 4539403. DOI: 10.4254/wjh.v7.i17.2100. View

Wang Y, Lu D, Xu Y, Xing W, Tong X, Wang G . A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation. Antimicrob Agents Chemother. 2015; 59(11):7061-72. PMC: 4604411. DOI: 10.1128/AAC.01558-15. View

Kwon H, Lok A . Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011; 8(5):275-84. DOI: 10.1038/nrgastro.2011.33. View

Throsby M, van den Brink E, Jongeneelen M, Poon L, Alard P, Cornelissen L . Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One. 2008; 3(12):e3942. PMC: 2596486. DOI: 10.1371/journal.pone.0003942. View

10.

Smither S, Eastaugh L, Steward J, Nelson M, Lenk R, Lever M . Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 2014; 104:153-5. DOI: 10.1016/j.antiviral.2014.01.012. View

11.

DiLillo D, Tan G, Palese P, Ravetch J . Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med. 2014; 20(2):143-51. PMC: 3966466. DOI: 10.1038/nm.3443. View

12.

Reich S, Guilligay D, Pflug A, Malet H, Berger I, Crepin T . Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature. 2014; 516(7531):361-6. DOI: 10.1038/nature14009. View

13.

Swanson K, Settembre E, Shaw C, Dey A, Rappuoli R, Mandl C . Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A. 2011; 108(23):9619-24. PMC: 3111287. DOI: 10.1073/pnas.1106536108. View

14.

Dreyfus C, Laursen N, Kwaks T, Zuijdgeest D, Khayat R, Ekiert D . Highly conserved protective epitopes on influenza B viruses. Science. 2012; 337(6100):1343-8. PMC: 3538841. DOI: 10.1126/science.1222908. View

15.

Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S . Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014; 105:17-21. DOI: 10.1016/j.antiviral.2014.02.014. View

16.

Fodor E . The RNA polymerase of influenza a virus: mechanisms of viral transcription and replication. Acta Virol. 2013; 57(2):113-22. DOI: 10.4149/av_2013_02_113. View

17.

DuBois R, Slavish P, Baughman B, Yun M, Bao J, Webby R . Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog. 2012; 8(8):e1002830. PMC: 3410894. DOI: 10.1371/journal.ppat.1002830. View

18.

Bedard K, Wang M, Proll S, Loo Y, Katze M, Gale Jr M . Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. J Virol. 2012; 86(13):7334-44. PMC: 3416323. DOI: 10.1128/JVI.06867-11. View

19.

Klumpp K, Crepin T . Capsid proteins of enveloped viruses as antiviral drug targets. Curr Opin Virol. 2014; 5:63-71. DOI: 10.1016/j.coviro.2014.02.002. View

20.

Brezillon N, Brunelle M, Massinet H, Giang E, Lamant C, DaSilva L . Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS One. 2011; 6(12):e25096. PMC: 3230577. DOI: 10.1371/journal.pone.0025096. View